Winslow Asset Management Inc. Purchases 1,657 Shares of Kenvue Inc. (NYSE:KVUE)

Winslow Asset Management Inc. raised its holdings in Kenvue Inc. (NYSE:KVUE) by 1.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 154,929 shares of the company’s stock after purchasing an additional 1,657 shares during the period. Winslow Asset Management Inc.’s holdings in Kenvue were worth $3,584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Kenvue by 13.8% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,800,461 shares of the company’s stock valued at $111,035,000 after acquiring an additional 583,887 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in Kenvue by 100.1% during the third quarter. Venturi Wealth Management LLC now owns 6,024 shares of the company’s stock valued at $139,000 after purchasing an additional 3,014 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the 3rd quarter valued at approximately $35,000. Intrinsic Value Partners LLC acquired a new position in shares of Kenvue in the 3rd quarter worth approximately $203,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Kenvue during the 3rd quarter worth approximately $213,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.4 %

Shares of Kenvue stock opened at $23.78 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.88. The stock has a market cap of $45.54 billion, a PE ratio of 43.24, a price-to-earnings-growth ratio of 3.10 and a beta of 1.36. The business has a fifty day simple moving average of $22.68 and a 200 day simple moving average of $20.58.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.41% and a net margin of 6.88%. The company’s revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.31 earnings per share. Research analysts predict that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.45%. Kenvue’s dividend payout ratio is 149.09%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research analyst reports. Piper Sandler upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. UBS Group boosted their price objective on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. raised their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.